Altogether, these results show a significant correlation between primary resistance to anti-CTLA-4 or anti-PD-1 and tumor MHC I/II expression, which has a strong potential as a predictive biomarker in ICI therapies. The gene discussed is CTLA4; the disease is neoplasm.